CD36 and fatty liver disease: Notably, the glycerophospholipid dysregulation aligns with recent mechanistic studies where lipid metabolism perturbations (specifically CD36-mediated pathways) directly drive hepatic steatosis pathogenesis, as demonstrated in CRISPR-Cas9-based NAFLD interventions targeting Rubicon [40].